Priced Oct 15, 2026 · range was $17–$19 · latest SEC filing Nov 10, 2026.
Pinch-zoom for details.
Clinical-stage biotech developing RNA-interference (RNAi) medicines that switch off disease-related proteins.
Fiscal year
1st half
Fiscal year
1st half
Fiscal year
1st half
| $ | FY2024 | FY2025 | YoY | H1 2025 | H1 2026 | Change |
|---|---|---|---|---|---|---|
| Revenue | 2.78M | 13.6M | +388% | 5.58M | 6.36M | +14.0% |
| Operating result | (29.1M) | (59.9M) | −106% | (26.6M) | (51.1M) | −92.3% |
| Net result | (27.8M) | (58.5M) | −110% | (24.3M) | (53.4M) | −120% |
| $ | FY2024 | FY2025 | YoY |
|---|---|---|---|
| Revenue | 2.78M | 13.6M | +388% |
| Operating result | (29.1M) | (59.9M) | −106% |
| Net result | (27.8M) | (58.5M) | −110% |
| $ | H1 2025 | H1 2026 | Change |
|---|---|---|---|
| Revenue | 5.58M | 6.36M | +14.0% |
| Operating result | (26.6M) | (51.1M) | −92.3% |
| Net result | (24.3M) | (53.4M) | −120% |
Values as filed, shortened (K = thousand, M = million, B = billion); losses in parentheses. Change columns compare each period with the same period a year earlier; a bigger loss shows as a negative change. Green is better for the company, red worse; n/m where the sign flips.
The filing doesn't set out its risks in a list we could read.
The filing's own strategy headings, shortened.
Source: CITY THERAPEUTICS, INC.'s Form 424B4, filed with the SEC on Oct 16, 2026 (final prospectus). Figures are as filed; changes are worked out from them. Not investment advice.
Pinch-zoom for details.
10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.
Infographic
Double-tap: full screen or back